Research Analysts Offer Predictions for ViewRay, Inc.’s Q3 2017 Earnings (NASDAQ:VRAY)
ViewRay, Inc. (NASDAQ:VRAY) – Stock analysts at Zacks Investment Research raised their Q3 2017 earnings per share (EPS) estimates for ViewRay in a report issued on Wednesday. Zacks Investment Research analyst A. Dushyanth now anticipates that the company will post earnings of ($0.11) per share for the quarter, up from their prior forecast of ($0.15). Zacks Investment Research also issued estimates for ViewRay’s Q4 2017 earnings at ($0.07) EPS and FY2018 earnings at ($0.11) EPS.
VRAY has been the subject of several other research reports. ValuEngine cut ViewRay from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Aegis restated a “buy” rating and set a $11.00 target price on shares of ViewRay in a research note on Saturday, July 22nd. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of ViewRay in a research note on Wednesday, May 17th. Northland Securities restated a “buy” rating and set a $7.00 target price on shares of ViewRay in a research note on Tuesday, May 16th. Finally, Cantor Fitzgerald began coverage on ViewRay in a research note on Thursday, June 29th. They set an “overweight” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $9.50.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/13/research-analysts-offer-predictions-for-viewray-inc-s-q3-2017-earnings-nasdaqvray.html.
ViewRay (NASDAQ:VRAY) opened at 5.49 on Friday. The stock’s market capitalization is $323.95 million. The company has a 50 day moving average of $5.78 and a 200 day moving average of $6.25. ViewRay has a 12 month low of $2.64 and a 12 month high of $10.39.
ViewRay (NASDAQ:VRAY) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.68 million. The firm’s revenue was up 133.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.32) earnings per share.
A number of large investors have recently modified their holdings of VRAY. Sequoia Financial Advisors LLC boosted its stake in shares of ViewRay by 25.0% in the first quarter. Sequoia Financial Advisors LLC now owns 25,000 shares of the company’s stock worth $213,000 after buying an additional 5,000 shares in the last quarter. EAM Investors LLC boosted its stake in shares of ViewRay by 7.0% in the second quarter. EAM Investors LLC now owns 202,713 shares of the company’s stock worth $1,312,000 after buying an additional 13,243 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of ViewRay by 843.2% in the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock worth $107,000 after buying an additional 14,789 shares in the last quarter. UBS Group AG boosted its stake in shares of ViewRay by 447.7% in the first quarter. UBS Group AG now owns 22,479 shares of the company’s stock worth $192,000 after buying an additional 18,375 shares in the last quarter. Finally, Highbridge Capital Management LLC purchased a new stake in shares of ViewRay during the first quarter worth $167,000. Institutional investors own 49.56% of the company’s stock.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Stock Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related stocks with our FREE daily email newsletter.